Adjunctive Therapies in Atopic Dermatitis: Understanding the Role of the Skin Barrier and Microbiome in Disease Management (Outcomes)

Program Description

Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by intense itch and eczematous lesions. A number of genetic, immunologic, and environmental factors combine in AD to disrupt skin barrier function. Pharmacists and pharmacy technicians should be aware of nonpharmacologic strategies to manage these triggers to reduce AD flares as well as traditional treatment regimens for AD. Additionally, the American Association of Dermatology (AAD) recommends the routine use of daily moisturizers to relieve symptoms and enhance skin hydration in patients with AD. This webinar will outline the importance of daily skin care practices and counseling points pharmacists and pharmacy technicians can share with patients about the use of OTC skin care products and moisturizers in improving the skin barrier and reducing symptoms associated with AD.

Target audience: Retail pharmacists

Type of activity: Application for pharmacists
Release date: April 24, 2023
Expiration date: April 24, 2025

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

Pharmacist Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the impact of atopic dermatitis (AD) on patients’ quality of life
• Analyze the role of ceramides, the skin barrier, and the skin microbiome in the pathogenesis of AD
• Provide recommendations for adjunctive OTC therapies that aim to restore skin barrier function in AD

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity numbers 0290-0000-23-169-H01-P and 0290-0000-23-143-H01-T. The activity is available for CE credit through April 24, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Timothy D. Gladwell, PharmD, BCPS, BCACP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Cynthia Borda, PharmD, MBA, RPh; Lauren Assennata; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Peter Lio, MD, medical reviewer, has the following to disclose:

Speaker: AbbVie, Eli Lilly, Galderma, Hyphens Pharma, Incyte, La Roche-Posay/L’Oreal, MyOR Diagnostics, ParentMD, Pfizer, Pierre-Fabre Dermatologie, Regeneron/Sanofi Genzyme

Advisory Board: AbbVie, Almirall, Amyris, Arbonne, ASLAN, Bodewell, Boston Skin Science, Bristol Myers Squibb, Burt’s Bees, Castle Biosciences, Codex Labs, Concerto Biosci, Dermavant, Dermira, DermVeda, Eli Lilly, Galderma, IntraDerm, Janssen, Johnson & Johnson, Kaleido Biosci, Kimberly Clark, LEO Pharma, Lipidor, L’Oreal, Menlo Therapeutics, Merck, Micreos, MyOR Diagnostics, Regeneron/Sanofi Genzyme, Sibel Health, Skinfix, Sonica, Theraplex, UCB, Unilever, Verrica, Yobee Care

Research: AbbVie, AOBiome, Eczema Foundation, National Eczema Association

Patent Holder: Theraplex AIM (Patent Pending)

Stock Options: Codex Labs, LearnSkin/Learn Health, MaskSense, Medable, Micreos, Modernizing Medicine, Yobee Care

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms